Zacks Investment Research downgraded American Renal Associates Holdings Inc (NYSE:ARA) to Sell in a report released today.
- Updated: October 11, 2016
Yesterday American Renal Associates Holdings Inc (NYSE:ARA) traded -1.84% lower at $17.58. The company’s 50-day moving average is $19.67 and its 200-day moving average is $24.49. The last closing price is down -28.21% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 621,115 shares of the stock were exchanged, up from an average trading volume of 130,706
Zacks Investment Research has downgraded American Renal Associates Holdings Inc (NYSE:ARA) to Sell in a report released on 10/11/2016.
Previously on 08/19/2016, Barclays Capital reported on American Renal Associates Holdings Inc (NYSE:ARA) lowered the target price from $31.00 to $29.00. At the time, this indicated a possible upside of 0.31%.
See Chart Below
American Renal Associates Holdings Inc has a 52 week low of $17.43 and a 52 week high of $29.65 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 4 brokers have issued a report on the stock. The consensus target price is $33.75 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About American Renal Associates Holdings Inc (NYSE:ARA)
American Renal Associates Holdings, Inc. is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company's segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD). It operates clinics through a joint venture (JV) model, in which it partners with local nephrologists to develop, own and operate dialysis clinics. Each of its clinics is maintained as a separate joint venture in which it has the controlling interest, and its nephrologist partners and other joint venture partners have a non-controlling interest. The Company opens over 20 de novo clinics each year. The Company has owned and operated over 190 dialysis clinics in partnership with approximately 350 nephrologist partners treating over 13,000 patients in over 20 states and the District of Columbia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.